Learning disabilities
Exam Tips
- In OSCEs, define with the triad: reduced intellectual function, reduced adaptive/social function, onset in childhood; then clearly distinguish from specific learning difficulties.
- Always state that behaviour that challenges is a presentation, not a diagnosis; first look for unmet need, pain, communication barriers, or environmental triggers.
- Use a structured severity framework (mild/moderate/severe/profound) linked to expected independence and support needs.
- Mention diagnostic overshadowing explicitly: physical and psychiatric illness are frequently missed in people with learning disability.
- For management stations, lead with reasonable adjustments, capacity assessment, and MDT support before medication.
- If discussing antipsychotics, include safety monitoring and time-limited review; if mentioning valproate, state teratogenic risk and pregnancy-prevention requirements.
Definition
A learning disability (intellectual disability) is a lifelong neurodevelopmental condition defined by significantly reduced intellectual functioning, impaired adaptive/social functioning, and onset in childhood (before adulthood). In UK clinical practice, diagnosis is based on functional impact in everyday life as well as cognitive testing, and it is distinct from specific learning difficulties such as dyslexia or dyspraxia.
Pathophysiology
Learning disability arises from disruption of brain development and maturation (neuronal proliferation, migration, synaptic organisation, and network connectivity) before, during, or soon after birth. Causes are heterogeneous: chromosomal/genetic syndromes (for example Down syndrome, Fragile X, Rett syndrome), congenital brain anomalies, prenatal teratogen/infection exposure (including alcohol, congenital rubella, Zika, and valproate exposure), perinatal hypoxic-ischaemic injury/extreme prematurity, and acquired early-childhood CNS injury (meningitis, encephalitis, trauma). The clinical phenotype reflects severity of global cognitive impairment plus adaptive-function limitations, and is commonly modified by coexisting autism, epilepsy, sensory impairment, and social adversity. For revision, use a severity-and-function visual framework (IQ range plus adaptive skills) as shown in standard paediatric neurodisability figures.
Risk Factors
- Chromosomal/genetic conditions (for example Down syndrome, Fragile X syndrome, Turner syndrome, Williams syndrome, Rett syndrome)
- Non-genetic congenital CNS malformations (for example hydrocephalus, microcephaly, some forms of spina bifida)
- Prenatal exposures: alcohol, sodium valproate, congenital rubella, Zika infection
- Very preterm birth (especially <33 weeks) and perinatal hypoxic brain injury/cerebral palsy
- Early childhood CNS disease or injury (meningitis, encephalitis, measles-related complications, traumatic/non-accidental brain injury)
- Early neglect and severe lack of developmental stimulation
- Coexisting neurodevelopmental disorders (autism, ADHD)
Clinical Features
Symptoms
- Delayed developmental milestones and slower acquisition of language/academic skills
- Difficulty understanding new or complex information
- Problems learning new skills and generalising learning
- Reduced independent functioning in daily life (self-care, budgeting, planning, time management)
- Communication difficulties (expressive and/or receptive), with possible social vulnerability
- Behaviour that challenges (for example aggression, self-injury, stereotypies, withdrawal), often triggered by unmet need, pain, sensory overload, or communication barriers
Signs
- Evidence of below-expected intellectual functioning on formal cognitive assessment
- Adaptive-function deficits across conceptual, social, and practical domains
- Need for support with activities of daily living (severity-dependent)
- Associated neurological/developmental signs (for example motor incoordination, sensory impairment, epilepsy-related findings)
- Physical health comorbidity signs (for example constipation, dysphagia, obesity/underweight, thyroid disease)
- Atypical presentation of mental illness due to communication and cognitive profile
Investigations
Management
Lifestyle Modifications
- Person-centred, multidisciplinary care plan (GP, community paediatrics, LD nurse, psychology, SALT, OT, physiotherapy, school/SEND services, social care)
- Reasonable adjustments: accessible communication, longer appointments, quiet environment, hospital passport use, carer/advocate involvement
- Family and carer education, respite planning, and safeguarding assessment where abuse/neglect risk is suspected
- Address triggers for behaviour that challenges first: pain, constipation, sleep disturbance, sensory overload, communication mismatch, environmental stress
- Annual health checks and proactive screening for physical/mental comorbidity
- Support participation, physical activity, healthy diet, oral health, continence and sleep routines
Pharmacological Treatment
No curative pharmacotherapy for core learning disability
- None for reversal of intellectual/adaptive impairment
Medication is used only for specific comorbid conditions or short-term management of severe risk; always combine with non-pharmacological and environmental interventions.
Behaviour that challenges (only when severe risk and psychological/environmental interventions are insufficient)
- Risperidone oral: 0.25 mg once daily if body weight <50 kg, or 0.5 mg once daily if >=50 kg; titrate cautiously according to response and adverse effects
Use time-limited prescribing with clear target behaviours and regular review. Safety: monitor weight/BMI, BP, glucose/lipids, extrapyramidal effects, sedation, and prolactin-related effects. Avoid using antipsychotics as sole long-term strategy for unmet social or communication needs.
Comorbid epilepsy (example dosing)
- Levetiracetam oral: start 10 mg/kg twice daily, increase in steps to usual maintenance up to 30 mg/kg twice daily (child dosing)
Choose antiepileptic by seizure type and specialist advice. Safety: mood/behavioural adverse effects can occur. If sodium valproate is considered in females of childbearing potential, follow MHRA pregnancy prevention requirements due to major teratogenic risk.
Comorbid constipation (common in LD)
- Macrogol 3350 paediatric oral powder: start 1 sachet daily (age-appropriate product), titrate to produce regular soft stool
Escalate bowel regimen early to prevent pain-related behaviour change and avoidable admission. Exclude red flags (obstruction, severe pain, vomiting, weight loss).
Complications
- Behaviour that challenges with risk of harm to self/others and potential restrictive interventions
- Physical multimorbidity (epilepsy, dysphagia with aspiration pneumonia risk, constipation, reflux, obesity/underweight, endocrine and cardiovascular disease)
- Mental health disorders (anxiety, depression, psychosis, bipolar disorder, self-harm, dementia risk in some groups such as Down syndrome)
- Diagnostic overshadowing and delayed diagnosis/treatment of acute illness
- Social complications: bullying, exploitation, exclusion, poverty, unemployment, housing instability
- Health inequalities, avoidable admissions, and increased premature mortality
Prognosis
Learning disability is lifelong and not curable, but outcomes improve with early, coordinated, person-centred support and active treatment of comorbidity. Population data show substantially reduced life expectancy versus the general population, with many deaths occurring before 65 years and a high proportion considered potentially avoidable; common causes include respiratory infection, congenital/chromosomal conditions, cardiovascular disease, and cancer.
Sources & References
💊BNF Drug References(1)
- Melatonin[management.pharmacological]
✅NICE Guidelines(1)
- Learning disabilities[overview]
📖Textbook References(13)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 61, 62)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1301, 1302)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 735, 736)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1690)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1692)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1691, 1692)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1220)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 61, 62)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 736)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 874)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 874)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 3016, 3017)[context]
- _OceanofPDF.com_Netters_Anatomy_-_8th_edition_-_Frank_H_Netter_MD.pdf(pp. 2504, 2505)[context]